Fees are a weakness here. The strategy's lofty fees are a high hurdle to clear, as it is priced within the second-highest quintile among peers.
Virtus KAR Health Sciences Inst HLHIX
- NAV / 1-Day Return 29.91 / −0.30 %
- Total Assets 140.2 Mil
-
Adj. Expense Ratio
1.120%
- Expense Ratio 1.120%
- Distribution Fee Level High
- Share Class Type Institutional
- Category Health
- Investment Style Large Growth
- Min. Initial Investment 1.0 Mil
- Status Open
- TTM Yield —
- Turnover 75%
USD | NAV as of Apr 19, 2024 | 1-Day Return as of Apr 19, 2024, 10:13 PM GMT+0
Morningstar’s Analysis HLHIX
Will HLHIX outperform in future?
Get our overall rating based on a fundamental assessment of the pillars below.
People Pillar
Parent Pillar
- Current Portfolio Date
- Equity Holdings —
- Bond Holdings —
- Other Holdings —
- % Assets in Top 10 Holdings 49.6
|
Top 10 Holdings
|
% Portfolio Weight
|
Market Value USD
|
Sector
|
|---|---|---|---|
Eli Lilly and Co | 9.33 | 13.2 Mil | Healthcare |
UnitedHealth Group Inc | 5.46 | 7.7 Mil | Healthcare |
IDEXX Laboratories Inc | 4.85 | 6.9 Mil | Healthcare |
AbbVie Inc | 4.75 | 6.7 Mil | Healthcare |
The Cooper Companies Inc | 4.74 | 6.7 Mil | Healthcare |
Zoetis Inc Class A | 4.44 | 6.3 Mil | Healthcare |
Merck & Co Inc | 4.11 | 5.8 Mil | Healthcare |
Vertex Pharmaceuticals Inc | 4.06 | 5.7 Mil | Healthcare |
West Pharmaceutical Services Inc | 3.96 | 5.6 Mil | Healthcare |
Danaher Corp | 3.86 | 5.5 Mil | Healthcare |